Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.3M Health Care and Greystone sign licensing agreement
This is the second agreement between 3M Health Care and Greystone Pharmaceuticals. The first agreement provided 3M Health Care distribution rights in Canada and parts of Europe. This
This is the second agreement between 3M Health Care and Greystone Pharmaceuticals. The first agreement provided 3M Health Care distribution rights in Canada and parts of Europe. This
Under the terms of the agreement, PTC will commercialize PTC124 in the US and Canada, and Genzyme will commercialize the treatment in all other countries. Genzyme will make
According to the company, the Sonatherm 600i system will be used to ablate certain soft tissue lesions, excluding the prostate gland, in general surgery. The company expects to
This is the initial acquisition for Dynova Laboratories, a new company with expertise in identifying and building successful over-the-counter (OTC) brands. Dynova’s objective is to bring to market
Schering-Plough’s Nasonex is an intranasal steroid that significantly improves nasal allergy symptoms when taken once each day. Nasonex is said to be the first intranasal steroid to be
In this position, Dr Bedigian will take the lead and be responsible for all medical aspects of Isis’s clinical development programs. Dr Bedigian comes to Isis from Novartis
Recombinant aflatoxin detoxifizyme (rADTZ) is said to be an innovative product that has the potential to detoxify aflatoxin (AFT), a potential cancer causing agent, in food and feed.
This multicenter, randomized, double-blind, dose-escalating, placebo-controlled study is evaluating the safety, tolerability, efficacy, and pharmacokinetics of a single dose of Adlea administered via injection following surgical closure of
MacroGenics will issue shares of its stock to purchase Raven. Montgomery & Co served as the financial advisor to Raven. Arnold & Porter served as legal advisor to
ALS-886 is a small molecule therapeutic that, in preclinical studies, has demonstrated efficacy in reducing and preventing tissue damage in the lungs. Defence Science and Technology Laboratory (Dstl)